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Summary
Somatic cell mutation frequency in vivo was measured in individuals with high cancer risk who were from
ataxia telangiectasia (A-T) families. The assay for somatic mutation measures the frequency of variant
erythrocytes which are progeny of erythroid precursor cells with mutations that result in a loss of gene ex-
pression at the polymorphic glycophorin A (GPA) locus. Samples from 14 of 15 A-T homozygotes showed
high frequencies of GPA gene expression-loss variant cells with normal expression of only one of the two
alleles at the GPA locus (i.e., GPA hemizygous variant cells). The mean elevation of the frequency of
hemizygous variant cells over those in normal controls and unaffected family members was 7-14-fold. A-T
homozygotes also showed an increase in the frequency of cells in which one allele at the GPA locus had
lost expression and in which the remaining allele was expressed at a homozygous level (i.e., GPA homozy-
gous variant cells). Family members who are obligate A-T heterozygotes did not appear to have a
significantly elevated frequency of GPA hemizygous or homozygous variant cells. These indications of
elevated in vivo frequencies of variant erythrocytes in A-T homozygotes support a causal link between sus-
ceptibility to somatic mutation and susceptibility to cancer.
Introduction
Ataxia telangiectasia (A-T) is an inherited autosomal
recessive syndrome, characterized by progressive cere-
bellar ataxia and oculocutaneous telangiectasia (Boder
1985), in which homozygotes have a very high cancer
risk (Spector et al. 1982). Heterozygotes, estimated to
comprise 0.68%-7.7% of the U.S. population (Swift
et al. 1986), also show a significant excess of cancer
and may represent an important proportion of cancer-
prone individuals in the general population (Swift et
al. 1987). We hypothesized that cancer susceptibility
of A-T homozygotes and heterozygotes could be related
to an increased rate of in vivo somatic mutation. To
directly assess in vivo mutability, we measured the ex-
pression of mutations in erythroid cells of members of
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A-T families by enumerating the frequency of glycopho-
rin A (GPA) variant erythrocytes in peripheral blood
samples (Langlois et al. 1986).
The assay is based on the autosomal GPA locus which
codes for the M and N blood group erythrocyte cell-
surface antigens. Because the MN blood phenotype
results from codominant allelic expression at the GPA
locus, nonlethal null mutations in either the M or the
N allele of erythroid precursor cells can be detected in-
dependently in our assay as hemizygous variant erythro-
cytes of No or MO phenotype in the peripheral blood
of individuals with MN blood type. Variant cells of
this phenotype may arise by several genetic mechanisms,
e.g., amino acid substitutions, deletions/insertions, as
well as chromosome aneuploidy or nonhomologous so-
matic recombination. With this same assay, homolo-
gous mitotic recombination, chromosome missegre-
gation, or gene conversion also can be detected as
homozygous variant cells of MM or NN phenotype
(Langlois et al. 1986). Our assay for detecting variant
erythrocytes that presumably result from in vivo muta-
tions at the GPA locus has demonstrated an increase
in somatic cell mutations both in humans exposed to
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mutagenic chemotherapy (Bigbee et al. 1987) and in
Hiroshima A-bomb survivors exposed to whole-body
high-energy radiation (Langlois et al. 1987). The per-
sistence of effects in A-bomb survivors who were ex-
posed in 1945 indicates that stem cells in the bone mar-
row were mutated at the GPA locus by ionizing radiation
and that these mutations continue to be expressed 40
years later as a high frequency of GPA variant erythro-
cytes in peripheral blood. The assay has also demon-
strated very high frequencies of GPA hemizygous and
homozygous variant erythrocytes in samples from
Bloom syndrome homozygotes (Langlois et al., in press).
Material and Methods
Blood Samples
Blood samples were obtained with informed consent
from members of 19 unrelated A-T families. Samples
were drawn into EDTA anticoagulant and were trans-
ported immediately to Livermore. As required for this
assay, only samples ofMN blood type (approximately
half of the total) were analyzed. All experimental anal-
yses were performed without knowledge of the A-T sta-
tus of the donors. A set of concurrent control samples
was analyzed together with the samples from the A-T
families. Most of the concurrent control samples were
obtained from local healthy individuals, although three
control blood samples were included in the coded ship-
ments of samples from the A-T families. No and NN
variant cell frequencies were obtained for samples from
24 concurrent control individuals, ages 29-61 years
(mean age 43 years). The ratio of smokers to nonsmok-
ers in this group was approximately 2:1. MO and MM
frequencies were obtained for samples from a subset
of 4 of these individuals, one of whom was a smoker.
Also included are variant-cell frequency data from an
independent set of historic control samples from healthy
individuals studied previously (Jensen et al. 1988). NO
and NN frequencies were obtained for samples from
54 historic control individuals, ages 1-84 years (mean
age 37 years). MO andMM frequencies were obtained
for samples from a subset of 23 of these individuals.
The ratio of smokers to nonsmokers in the historic con-
trol group was approximately 1:5.
GPA Analysis
GPA variant-cell frequencies were determined using
the GPA in vivo somatic cell mutation assay as described
elsewhere (Langlois et al. 1986). In brief, fixed periph-
eral blood erythrocytes are simultaneously immuno-
labeled with two GPA-specific monoclonal antibodies
coupled to one of the distinguishable fluorophors, fluor-
escein (green fluorescence) or Texas RedTm (red fluores-
cence). Normal cells bind both antibodies and display
two-color fluorescence, whereas variant cells, which fail
to bind a GPA allele-specific antibody, are only singly
labeled. Hemizygous No and homozygousNN variant
cells are enumerated by labeling with a fluoresceinated
GPA-specific "public" monoclonal antibody, 10F7,
which recognizes both allelic forms of GPA, and with
a biotinylated GPA(M)-specific monoclonal antibody,
6A7, followed by Texas Red-conjugated avidin. Cells
of hemizygous NO phenotype (loss of expression of the
M allele) fail to bind 6A7, exhibit only background
Texas Red fluorescence, and have one-half the normal
10F7 fluorescein fluorescence resulting from expression
of the single N allele. Homozygous NN cells also fail
to bind 6A7 but display normal 10F7 fluorescein fluores-
cence resulting from homozygous expression of the N
allele. Hemizygous MO> and homozygousMM variant
cells are enumerated by labeling with a fluoresceinated
GPA(M)-specific monoclonal antibody, 9A3, and with
a biotinylated GPA(N)-specific monoclonal antibody,
NN-3, followed by Texas Red-conjugated avidin. Cells
of hemizygous MO phenotype (loss of expression of
theN allele) fail to bind NN3, exhibit only background
Texas Red fluorescence, and have 9A3 fluorescein
fluorescence characteristic of the expression of a single
M allele. Homozygous MM cells also fail to bind
NN3 but exhibit 9A3 fluorescein fluorescence at a
homozygous level of expression of the M allele. The
antibody-labeled cell population is analyzed using a
dual laser-beam flow sorter which provides individual
excitation and detection of each fluorophor. Objects
with single-color fluorescence intensities characteristic
of hemizygous or homozygous variant erythrocytes are
identified and sorted onto microscope slides for visual
confirmation. For each sample, approximately 106
cells are analyzed; the variant cell frequency (Vf) is
reported as the number of microscopically verified
single-color erythrocytes per million total cells.
Statistical Analysis
On decoding, a preliminary statistical analysis of the
distributions of the A-T family and of the control group
Vf's revealed that the distributions were not normally
distributed (Kolmogorov-Smirnov test). Therefore the
distribution-free, nonparametric, two-sided, Mann-
Whitney test was used to estimate the probability, P,
of the identity of each A-T family group with each of





Concurrent with the measurement of GPA Vf's in
samples from the A-T families, data were also obtained
for samples from normal individuals. These samples
were obtained from 21 local donors and from 3 indi-
viduals whose blood was included in shipments of sam-
ples from the A-T families. The Vf's observed for these
three samples fell within the range observed for fresh
samples from local controls. Thus, as we found else-
where (Langlois et al. 1987), storage and shipment of
blood does not appear to affect Vf's in normal sam-
ples. Since the group of concurrent control samples was
rather small, Vf's determined in previous studies of 54
normal donors were also used for comparison with the
A-T families. The concurrent and historic control popu-
lations are similar in age distribution (mean ages of
43 and 37 years, respectively). The concurrent control
group contains a higher proportion of cigarette smokers,
2:1, versus 1:5 for the historic control group. Our studies
suggest a small smoking effect in the GPA assay; the
mean hemizygous Vf appears to be increased by
rv20% in smokers over that in nonsmokers, although
the increase is not statistically significant (W. L. Big-
bee, R. G. Langlois, and R. H. Jensen, unpublished
results). As shown in figure 1 and table 1, the distribu-
tions of No, NN, and MM Vf's are very similar for
the two control groups and do not differ significantly
(P = .572, .972, and .354, respectively); however the
MO distributions appear to differ (P = .006). This in-
dication of a difference in MO Vf's between the two
control groups must be viewed with caution given the
small number of samples (four) in the concurrent con-
trol group.
A-T Families
As shown in figure 1, the majority of blood samples
from A-T homozygotes contain a very high frequency
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Figure I GPA hemizygous Vf'S in peripheral blood of individuals from A-T families and of normal controls. Blood samples were simul-
taneously immunolabeled with two GPA-specific monoclonal antibodies and were analyzed by flow cytometry, and the variant erythrocytes
were enumerated using cell sorting as described in Material and Methods. A, GPA hemizygous No variant cells; B, GPA hemizygous MO
variant cells (about half the MN blood samples were analyzed by this second, independent assay). Vf's are plotted for A-T homozygotes,
for A-T parents (=mothers or fathers of A-T homozygotes), for other family(= brothers, sisters, aunts, uncles, grandmothers, or grandfathers
of A-T homozygotes), for concurrent controls, and for historic controls. Concurrent controls are healthy individuals sampled and analyzed
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Table I
Frequencies of GPA Variant Erythrocytes in Ataxia
Telangiectasia (A-T) Families, Compared with
Those in Controls
Donors (N) Range Median Mean (SD)
NO Variant Frequency per 106 Cells
A-T homozygotes (15) ...... 2-168 89 94 (50
A-T parents (23) ........... 1-22 8 8 (5)
Other family (33) .......... 1-84 7 13 (17)
Concurrent controls (24) .... 2-25 10 12 (7)
Historic controls (54) ....... 1-30 10 11 (7)
MO Variant Frequency per 106 Cells4
A-T homozygotes (9) ....... 22-417 138 144 (128)
A-T parents (12) ........... 10-33 17 20 (8)
Other family (7) ........... 3-23 14 13 (6)
Concurrent controls (4) ..... 14-27 20 20 (5)
Historic controls (23) ....... 2-21 9 10 (5)
NN Variant Frequency per 106 Cells
A-T homozygotes (15) ...... 0-140 14 43 (52)
A-T parents (23) ........... 0-114 9 17 (25)
Other family (33) .......... 1-161 10 23 (38)
Concurrent controls (24) ... 3-137 16 28 (32)
Historic controls (54) ....... 1-155 14 28 (29)
MM Variant Frequency per 106 Cellsa
A-T homozygotes (9) ....... 2-100 33 41 (35)
A-T parents (12) ........... 0-66 4 10 (18)
Other family (7) ........... 0-6 1 2 (2)
Concurrent controls (4) ..... 3-23 10 12 (8)
Historic controls (23) ....... 1-36 4 10 (11)
a A subgroup of the A-T samples that were analyzed for NO and
NN Vf's also were analyzed for MO and MM Vf's.
Vf's are elevated 8-fold (for NO) and 7-14-fold (for
MO) over the levels in the two groups of controls (table
1), and both elevations are highly significant (No vs.
historic and concurrent controls P < .001; M) vs.
historic controls P < .001, vs. concurrent controls P
= .016). No and MO Vf's in the A-T homozygote sam-
ples are also significantly elevated over those observed
in samples from the A-T parents and other family mem-
bers (P < .002 for all).
While 12 of the 15 A-T homozygotes had clearly high
No and MO Vf's, 3 showed a No or MO Vf within the
normal range (fig. 1, table 1): for donor 167, No =
89/million and MO = 22/million; for donor 266, No
= 34/million and MO = 23/million; and for donor
234, No = 2/million and MO was not measured. The
low MO Vf in donor 167 may reflect experimental er-
ror in the single measurement performed on this sam-
ple, as our experience with the assay indicates the
coefficient of variation of individual measurements can
be as large ".60% (Langlois et al. 1987); for the other
two A-T homozygotes, however, the normal Vf's were
confirmed by replicate measurements on independently
fixed and labeled cell aliquots. Alternatively, the A-T
phenotype is genetically heterogeneous (Paterson et al.
1977; Inoue et al. 1981; Murnane and Painter 1982;
Jaspers and Bootsma 1982; Chen et al. 1984), and thus
it is possible that these normal Vt's reflect genetic het-
erogeneity in susceptibility of A-T homozygotes to so-
matic mutation, with high susceptibility being common
but not universal.
Parents of A-T homozygotes, who are obligate A-T
heterozygotes, show a statistically significant (P < .001)
elevation of MO Vf's over the levels in the historic con-
trols; however, no significant increase over the levels
in the smaller set of concurrent controls was observed.
There was also no significant elevation ofNo Vf's over
the levels in either historic or concurrent controls. While
more than half of the other family members are ex-
pected to be A-T heterozygotes, this group showed no
difference from controls in either NO or MO Vf's, nor
is there evidence for a bimodal distribution of N4 or
MO Vf's in these samples. However, three individuals
in this group showed N4 Vf's above the normal range
(42, 58, and 84/million; MO Vf's were not measured).
The frequencies of GPA homozygous NN and MM
variant cells were also determined (table 1). The mean
MM Vf in A-T homozygotes is elevated fourfold over
that observed in A-T family members, and controls. This
elevation is significant compared with levels in the A-T
parents (P = .017), other family members (P = .002),
and historic controls (P = .008) but is not significant
compared with those in the small set of concurrent con-
trols (P = .190). The NN Vf's in samples from the A-T
families and in those from controls were quite variable,
owing in large part to antibody-labeling artifacts which,
in this version of the assay, produce high NN frequen-
cies in occasional samples (Langlois et al. 1986). Given
this dispersion of the data, there are no significant differ-
ences in NN Vf's between any of the A-T family groups
and controls, although the mean NN Vf in the A-T
homozygotes appears to be elevated.
Discussion
Compared with controls, A-T homozygotes have a
significantly elevated level of hemizygous No and MO
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variant erythrocytes. In addition, these individuals may
have an increased frequency of homozygous NN and
MM variant cells. These results provide clear evidence
for a high background frequency of gene expression-
loss somatic mutations in vivo in A-T homozygotes.
Previous reports of elevated background levels of chro-
mosome aberrations (for review, see McKinnon 1987)
and of micronuclei in exfoliated cells (Rosin and Ochs
1986) are also consistent with spontaneous genetic in-
stability in vivo in these individuals. In vitro studies,
in contrast, have suggested near-normal background
mutation frequencies for A-T cells (Arlett and Harcourt
1981; Simons 1982) and hypomutability of these cells
by ionizing radiation (Arlett and Harcourt 1978; Arlett
1980; Tatsumi and Takebe 1984). Since spontaneous
in vitro mutation frequencies are affected by time in
culture and by the rate of cell doublings (Simons 1982),
it is unclear whether A-T cells differ from normal cells
in spontaneous mutation rate. Fluctuation experiments
may be needed to clarify this point with regard to cul-
tured cells (Arlett and Harcourt 1981). While our results
do not provide any new information on induced muta-
tions in A-T, it seems possible that the genetic defect(s)
in these individuals could produce a high background
mutation frequency but no increase in induced muta-
bility by radiation.
A-T heterozygotes do not display a consistent eleva-
tion of Vf's in the GPA assay. Some of the data suggest
an increase; MO Vf's of the A-T parents are significantly
elevated over those in historic controls, and three sam-
ples from other family members showed No Vf's above
the normal range. However, the MO Vf's in the A-T
parents are not significantly elevated over those in the
concurrent controls, and the No Vf's in the A-T par-
ents are not elevated over those in either control group.
The three high Vf's observed in the other family mem-
bers may indicate that there are A-T heterozygotes who
are particularly susceptible to mutagenesis or who may
have experienced higher incidental mutagenic exposure
than did other family members who were assayed. One
of these individuals had received previous radiation ther-
apy for breast cancer. No genetic evidence of differ-
ences in susceptibility are apparent, as no exception-
ally high Vf's were observed for other members of these
A-T families. Thus, A-T heterozygotes may have a back-
ground mutation frequency higher than that in normal
individuals, but the difference is too small to detect with
this assay.
Other studies, however, suggest that A-T heterozy-
gotes, while lacking the clinical features of A-T, have
subtle cytological abnormalities and increased cancer
risk. A-T heterozygotes display elevated levels of
micronuclei in exfoliated epithelial cells (Rosin and Ochs
1986). Cultured fibroblasts and PHA-stimulated lym-
phocytes from A-T heterozygotes generally show an in-
creased level of background chromosome aberrations
and hypersensitivity to killing by X-irradiation (Gropp
and Flatz 1967; Schmid and Jerusalem 1972; Harnden
1974; Rary et al. 1974; Cohen et al. 1975; Oxford et
al. 1975; Levitt et al. 1978; Al Saadi et al. 1980). How-
ever, compared with normal cells, in these cells X-ir-
radiation does not induce an increase in cytogenetic
abnormalities, except for one report of increased chro-
matid damage (Parshad et al. 1985). Also, in sensitivity
to killing, inhibition of DNA synthesis, and level of
cytogenetic damage by DNA-damaging agents to which
homozygous A-T cells are hypersensitive, heterozygous
A-T cells appear to be similar to normal cells (for re-
view, see McKinnon 1987). Thus, A-T heterozygotes
appear to have a spectrum of subtle cytological defects,
possibly including mutation, which could be responsi-
ble for the increased risk of cancer seen in epidemio-
logic studies of these individuals (Swift et al. 1987).
The significance of our GPA-based mutational end-
point in estimating cancer risk has not yet been deter-
mined. However, it is clear that mutagenesis is an initi-
ation event in some neoplasia (for review, see Borg
1985), and oncogene activation by mutation has been
demonstrated (Brodeur 1986). In addition, loss of wild-
type alleles of "tumor supressor genes" by several genetic
mechanisms, including gene deletion or inactivation,
recombination, and chromosome loss, has been ob-
served in a wide variety of human tumors (Friend et
al. 1988). The GPA mutation assay may provide a mea-
sure of each individual's initiation susceptibility; an
estimate of overall risk will also require a means for
assessing individual susceptibility to other steps in neo-
plasia, such as stimulation of tumorigenic growth by
promoters.
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